BioCardia Inc (Nasdaq:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced on Monday that the Japan Patent Office has granted Japanese Patent No. 7641330 for its Helix biotherapeutic delivery system.

Titled 'Radial and Transendocardial Delivery Catheter', the patent is set to expire on or after 30 September 2034.

The new patent covers BioCardia's minimally invasive catheter technology designed to deliver biologic therapies directly to the heart. This approach enables targeted treatment, reduces off-target effects and eliminates the need for surgical access.

BioCardia believes its Helix System is the only catheter-based intramyocardial delivery system currently in active clinical use.

The company holds a broad portfolio of patents and applications covering cell, exosome and microRNA biotherapeutics, as well as advanced cardiac imaging technologies.